- Home
- TRUE vs VTYX Comparison
TRUE vs VTYX Comparison
Compare TRUE & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRUE
- VTYX
- Stock Information
- Founded
- TRUE 2005
- VTYX 2018
- Country
- TRUE United States
- VTYX United States
- Employees
- TRUE N/A
- VTYX N/A
- Industry
- TRUE Computer Software: Programming Data Processing
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- TRUE Technology
- VTYX Health Care
- Exchange
- TRUE Nasdaq
- VTYX Nasdaq
- Market Cap
- TRUE 175.1M
- VTYX 154.9M
- IPO Year
- TRUE 2014
- VTYX 2021
- Fundamental
- Price
- TRUE $1.60
- VTYX $3.83
- Analyst Decision
- TRUE Hold
- VTYX Buy
- Analyst Count
- TRUE 5
- VTYX 3
- Target Price
- TRUE $3.33
- VTYX $10.00
- AVG Volume (30 Days)
- TRUE 348.8K
- VTYX 1.4M
- Earning Date
- TRUE 11-05-2025
- VTYX 11-06-2025
- Dividend Yield
- TRUE N/A
- VTYX N/A
- EPS Growth
- TRUE N/A
- VTYX N/A
- EPS
- TRUE N/A
- VTYX N/A
- Revenue
- TRUE $184,559,000.00
- VTYX N/A
- Revenue This Year
- TRUE $8.42
- VTYX N/A
- Revenue Next Year
- TRUE $5.64
- VTYX N/A
- P/E Ratio
- TRUE N/A
- VTYX N/A
- Revenue Growth
- TRUE 11.66
- VTYX N/A
- 52 Week Low
- TRUE $1.05
- VTYX $0.78
- 52 Week High
- TRUE $4.62
- VTYX $4.05
- Technical
- Relative Strength Index (RSI)
- TRUE 35.47
- VTYX 72.30
- Support Level
- TRUE $1.51
- VTYX $2.64
- Resistance Level
- TRUE $1.89
- VTYX $3.92
- Average True Range (ATR)
- TRUE 0.13
- VTYX 0.31
- MACD
- TRUE -0.07
- VTYX 0.13
- Stochastic Oscillator
- TRUE 8.54
- VTYX 90.29
About TRUE TrueCar Inc.
TrueCar Inc is a data-driven online platform operating on common technology infrastructure, powered by proprietary data and analytics. It also customizes and operates its platform for affinity group marketing partners, including financial institutions like PenFed and American Express; membership-based organizations like Consumer Reports, AARP, Sam's Club, and AAA; and employee buying programs for large enterprises such as IBM and Walmart. The Company has one operating segment, with three distinct service offerings: Dealer products and services, OEM incentives, and other.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.